[CYTOSTATICS IN DERMATOLOGY. DOES THE ORAL OR INTRAVENOUS USE OF 2,3,5-TRISETHYLENEIMINOBENZOQUINONE (1,4) MEAN A PROGRESS IN THE TREATMENT OF MALIGNANT RETICULOSES AND GRANULOMATOSES OF THE SKIN?].
D000970:Antineoplastic Agents; D001943:Breast Neoplasms; D054697:Cytostatic Agents; D003880:Dermatology; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse; D008228:Lymphoma, Non-Hodgkin; D008545:Melanoma; D009182:Mycosis Fungoides; D009362:Neoplasm Metastasis; D009369:Neoplasms; D020135:Peptide Nucleic Acids; D012509:Sarcoma; D012878:Skin Neoplasms
D000970:Antineoplastic Agents; D054697:Cytostatic Agents; D020135:Peptide Nucleic Acids
ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; MELANOMA; MYCOSIS FUNGOIDES; NEOPLASM METASTASIS; SARCOMA, RETICULUM CELL; SKIN NEOPLASMS
ZYTOSTATIKA IN DER DERMATOLOGIE. BEDEUTET DIE ORALE BZW. INTRAVENOESE ANWENDUNG VON 2,3,5-TRIS-AETHYLENIMINO-BENZOCHINON(1,4) EINEN FORTSCHRITT BEI DER BEHANDLUNG MALIGNER RETIKULOSEN UND GRANULOMATOSEN DER HAUT?